The induction and maintenance of oncogenic transformation requires interference with the controls that regulate translation and transcription. The PI 3-kinase pathway, which shows gain of function in numerous and diverse human cancers, generates signals that have a positive effect on the initiation of protein synthesis. Here we review the components of the PI 3-kinase signaling pathway and the mRNA-binding protein YB-1, exploring their roles in protein synthesis and oncogenic cell transformation.
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The prevailing interpretation of oncogenesis sees cancer as arising from a change in transcriptional controls with characteristic properties of the cancer cell determined at the level of transcription. Differential transcription is of evident importance in oncogenesis; numerous oncogenes code for transcriptional regulators, and proteins that mediate chromatin remodeling have profound effects on cellular growth behavior (Hesketh, 1997; Dalla-Favera, 2001; Ito, 2003; Katsani et al., 2003) . The focus on transcription is reflected in the popular use of DNA microarrays for the characterization of tumor transcriptoms (Liu, 2003; Russo et al., 2003) . However, the exclusive emphasis on transcription overlooks another mechanism of gene regulation: the control of translation. Yet there is increasing evidence for an important, even essential role of differential protein synthesis in cancer (Clemens and Bommer, 1999; Zimmer et al., 2000; Rajasekhar et al., 2003) . As transcriptional controls in cancer target specific genes, so do translational controls: they preferentially affect certain mRNAs. The mechanisms for this selectivity are only beginning to be understood.
Evidence for an essential role of protein synthesis in oncogenic transformation has emerged from studies on phosphoinositide 3-kinase (PI3K). In response to upstream signals, PI3K phosphorylates phosphatidylinositol at the D3 position, generating phosphatidylinositol-3,4-bisphosphate and phosphatidylinositol-3,4,5-trisphosphate (Cantley, 2002) . This process is negatively regulated by the lipid phosphatase PTEN (phosphatase and tensin homolog deleted on chromosome 10), which dephosphorylates the products of PI3K at their D3 positions and functions as a PI3K antagonist (Simpson and Parsons, 2001) . It is also an important and essential tumor suppressor that is frequently deleted in human cancers. The products of PI3K are recognized by the pleckstrin homology domains of two Ser-Thr kinases, Akt and PDK1, providing a common docking platform for these kinases. PDK1 phosphorylates and thereby activates Akt; a second kinase may also contribute to Akt activation (Chan et al., 1999; Scheid and Woodgett, 2001 ). Akt in turn has numerous protein targets, including several proapoptotic proteins and tumor suppressors, which are downregulated by Akt-dependent phosphorylation as well as growth-promoting proteins that are upregulated. Examples for targets that are negatively regulated by Akt are BAD, BRCA1 (breast cancer susceptibility gene product), caspase 9, glycogen synthase kinase-3 beta, the protein kinase Raf and the forkhead transcription factors FKHR, FKHR-L1 and AFX (Cross et al., 1995; Datta et al., 1997; del Peso et al., 1997; Cardone et al., 1998; Altiok et al., 1999; Biggs et al., 1999; Brunet et al., 1999; Kops et al., 1999; Rommel et al., 1999; Zimmermann and Moelling, 1999; Miralem and Avraham, 2003) . Examples for proteins that are positively regulated by Akt are the kinase IKK a, a positive regulator of nuclear factor kB (NFkB), and the Ser/Thr kinase TOR (target of rapamycin) (Kane et al., 1999; Nave et al., 1999; Ozes et al., 1999; Romashkova and Makarov, 1999) .
The catalytic subunit of PI3K, p110 and Akt have both been found as oncoproteins encoded by acutely transforming retroviruses (Bellacosa et al., 1991; Chang et al., 1997) . A homolog of p110, termed P3K, was discovered as the oncoprotein of the avian sarcoma virus ASV16. ASV16 induces transformation in chicken embryo cell cultures and causes highly aggressive hemangiosarcomas in the animal (Chang et al., 1997) . Akt is the oncoprotein of the murine retrovirus Akt8, originally isolated from a spontaneous thymoma (Staal et al., 1977) . Akt, expressed by an avian retroviral vector, transforms avian embryo cells and in chickens also induces hemangiosarcomas indistinguishable from those caused by P3K (Aoki et al., 1998) . The acute transforming activities of P3K and Akt in cell culture require a gain of function. To be oncogenic, both P3K and Akt need a structurally and functionally intact kinase domain and a strong constitutive membrane address (Aoki et al., 1998; Aoki et al., 2000) . The membrane address can be provided by fusion to sequences of the retroviral Gag protein or by a myristylation or a farnesylation signal. In the case of Akt, a gain of function mutation in the pleckstrin homology domain is also effective (Aoki et al., 1998) .
An important role of protein synthesis in oncogenic transformation induced by P3K and Akt is suggested by the effect of rapamycin on transformation induced by these two oncoproteins. Rapamycin is a macrolide antibiotic derived from Streptomyces hygroscopicus (Hamilton and Steiner, 1998; Vezina et al., 1975) . Its cellular receptor is the peptidyl-prolyl trans-isomerase FKBP12 (FK506-binding protein). The rapamycin-FKBP12 complex binds to the target of rapamycin, TOR, and inhibits this protein kinase. TOR belongs to the family of PI3K-related protein kinases. It is activated by the PI3K/Akt pathway and has numerous and diverse cellular functions (Schmelzle and Hall, 2000; Abraham, 2004; Gingras et al., 2004; Jaeschke et al., 2004; Proud, 2004) . TOR is a sensor of nutrient status, a regulator of transcription (notably POLI-and POLIIIdependent transcription), and an indirect regulator of protein synthesis. The latter function is mediated by TOR-dependent phosphorylation of p70 S6 kinase (S6K) and of 4E-binding proteins (4E-BPs) (Sonenberg and Gingras, 1998; Dufner and Thomas, 1999; Gingras et al., 2001; Gingras et al., 2004) . S6K is activated by TOR-mediated phosphorylation. 4E-BPs are negative regulators of translation, and this function is inactivated by TOR-dependent phosphorylation. 4E-BPs bind to eucaryotic initiation factor 4E (eIF4E), the cap-binding component of the translational initiation complex 4F and prevent 4E from forming this complex. Phosphorylation of 4E-BPs by TOR leads to dissociation from 4E, effectively debilitating the 4E-BPs and releasing 4E for its function in translational initiation (Brunn et al., 1997; Burnett et al., 1998; Raught and Gingras, 1999; Gingras et al., 2004) .
The oncogenic activities of P3K and Akt in cell culture are exquisitely sensitive to rapamycin; 1 ng/ml of the drug completely inhibits the formation of transformed cell foci (Aoki et al., 2001) . Rapamycin also induces reversion of cells transformed by P3K or Akt to normal morphology (Bader and Vogt, 2001, unpublished data) . Surprisingly, the antioncogenic activity of rapamycin is specific for P3K and Akt. It does not extend to transformation induced in chicken embryo cell cultures by other oncoproteins such as Src, Jun, Yes, Sea, Abl, ErbA/ErbB, Crk, Mos, Fos or Myc (Aoki et al., 2001 ). Yet, resistance to rapamycin may not rule out participation of TOR in the signals issued by these oncoproteins. In the case of Src, rapamycin becomes inhibitory for oncogenic transformation if it is applied in conjunction with an inhibitor of the MAP kinase pathway, whereas either drug alone fails to affect Srcinduced transformation (Penuel and Martin, 1999) . Recent data show an inhibitory effect of Src on PTEN resulting in increased activation of Akt (Lu et al., 2003) . These observations suggest that the oncogenic signal from Src can be transmitted via alternative pathways, MAP dependent or PI 3-kinase dependent.
TOR-mediated activation of S6K and phosphorylation of 4E-BP resulting in activation of 4E affect specific sets of mRNAs. S6K enhances translation of 5 0 TOP messages, which code for basic components of the translational machinery (Jefferies et al., 1997; Meyuhas, 2000) . 4E stimulates translation of mRNAs with complex secondary structures in their 5 0 untranslated regions. Many of these messages code for growth-related proteins including growth factors, receptors, kinases, transcriptional regulators and cell cycle proteins (Zimmer et al., 2000) .
In chicken embryo fibroblasts transformed by either P3K or Akt, both S6K and 4E-BP are constitutively phosphorylated, whereas in normal cells such phosphorylation requires signaling by a growth factor (Aoki et al., 2001) . A mutant of Akt in which the two activating phosphorylation sites T308 and S473 are replaced by phosphomimetic D residues retains kinase activity but fails to transform chicken embryo fibroblasts (Aoki et al., 1998) . This mutant also does not induce the constitutive phosphorylation of S6K and 4E-BP (Aoki et al., 2001) . Rapamycin interferes with the constitutive phosphorylation of S6K and 4E-BP in transformed cells (Aoki et al., 2001) . These observations document a correlation between S6K and 4E-BP phosphorylation and P3K-and Akt-induced oncogenic transformation. They also suggest that differential protein synthesis affecting the translation of specific mRNAs is an essential component of the process of P3K-or Aktinduced oncogenesis.
Specific inhibition of P3K-and Akt-induced transformation can also be induced by the Y-box-binding protein, YB-1 (Bader et al., 2003) . Chicken embryo cells transformed by either P3K or Akt show reduced levels of YB-1 mRNA, whereas transformation by other oncoproteins such as Src, Jun or Qin does not affect YB-1 mRNA levels. Chicken embryo cells that express YB-1 from a retroviral vector become solidly resistant to transformation by P3K and Akt, but remain susceptible to other oncoproteins. YB-1, also known as p50 or DNA-binding protein B (dbpb), is a member of the cold shock protein family and binds to single-stranded RNA, single-stranded DNA and double-stranded DNA (Evdokimova and Ovchinnikov, 1999; Izumi et al., 2001) . It is a multifunctional protein, controlling both transcription and translation. As a mRNA-binding protein, it is the most abundant protein in messenger ribonucleoprotein particles (mRNPs), is located in the cytoplasm and regulates translation in a dose-dependent manner (Blobel, 1972; Barrieux et al., 1976; Koike et al., 1997; Zhang et al., 2003c) . Low concentrations promote translation, higher ones are inhibitory (Minich and Ovchinnikov, 1992; Nekrasov et al., 2003) . As a DNA-binding protein, YB-1 binds to the Y box promoter element containing an inverted CCAAT box and either activates or represses transcription (Ting et al., 1994; Mertens et al., 1997; Didier et al., 1988) . The inhibition of protein synthesis seen with elevated concentrations of YB-1 may reflect a masking of mRNA that prevents access of the translational machinery (Sommerville and Ladomery, 1996; Evdokimova and Ovchinnikov, 1999) . Inactive mRNPs contain about two times more YB-1 protein than active mRNPs (Minich and Ovchinnikov, 1992 ). An alternative mechanism to nonspecific masking is binding to a specific site in mRNA or a component of the translation initiation complex. YB-1 binds to the cap structure of mRNA, and it has been suggested that YB-1 competes with 4E for this site (Evdokimova et al., 2001; Bader et al., 2003) . There is also evidence that YB-1 prevents the association of the eucaryotic initiation factor 4G with mRNA, interfering with assembly of the 4F translation initiation complex (Nekrasov et al., 2003) .
Available data on the YB-1-induced resistance to P3K and Akt favor a mechanism involving control of protein synthesis (Bader et al., 2003) . Inhibition of P3K and Akt by YB-1 is correlated with reduced levels of capdependent and cap-independent protein synthesis. A mutant of YB-1 that has lost its ability to bind to RNA and no longer interacts with the mRNA cap structure also fails to interfere with P3K and Akt-induced transformation and does not reduce levels of protein synthesis. Phenotypically, YB-1 acts like a rapamycin mimic, but its mechanism of action appears to be fundamentally different, with a probable site of action downstream of TOR and possibly of the TOR targets S6K and 4E-BP.
The data from in vitro studies are complemented by experiments in animals with tumors that show a gain of function in PI3K signaling Podsypanina et al., 2001) . Mice that are heterozygous for an inactivating mutation of PTEN suffer an increased incidence of uterine and adrenal medullary tumors (Podsypanina et al., 2001) . In the neoplastic lesions, PTEN expression is reduced or absent, and S6K is activated as judged by its phosphorylation status and by immune complex kinase assays. Treatment of these mice with the rapamycin analog CCI 779 inhibits tumor development and leads to reduced activity of S6K. However, the high levels of phosphorylated Akt characteristic of PTEN deficiency are not changed by CCI 779 treatment. A related study analysed human tumor cell lines that lack PTEN . Key findings are an increase of phosphorylated S6 ribosomal protein as well as total S6 in PTEN-deficient cells as compared to wild-type cells. The amount and phosphorylation status of S6 in the PTEN-negative cells is highly sensitive to CCI 779. Similarly, 4E-BP is mostly phosphorylated and hence inactivated in PTEN-null cells, but becomes dephosphorylated in the presence of CCI 779. Again, the status of Akt is not affected by the drug. The formation of tumors by PTEN-deficient human cancer cells in SCID mice is inhibited by CCI 779, in parallel with a reduction in levels and phosphorylation status of S6K and the dephosphorylation of 4E-BP. Growth of tumor cells in the presence of increasing doses of rapamycin leads to the selection of rapamycinresistant variants. Resistance to rapamycin is correlated with downregulation of 4E-BP, resulting in a lowered ratio of 4E-BP to 4E and hence increased availability of 4E (Dilling et al., 2002) .
Studies in vitro and in vivo provide evidence for an essential role of protein synthesis oncogenic transformation that is driven by a gain of function in PI3K signaling. Although levels of protein synthesis are elevated across the board in PI3K-dependent transformation, it is likely that only specific growth-related mRNAs need to be translated differentially to induce and sustain the oncogenic phenotype. Differential protein synthesis is essential but probably not sufficient for oncogenicity. Germline mutations in TSC do not drastically increase the incidence of invasive cancers, and overexpression of TOR has failed to induce oncogenic transformation in cell culture (Asai and Vogt, 2002, unpublished observation; Kwiatkowski, 2003; Zhang et al., 2003a) . Transcriptional signals may have to complement enhanced translation. Transformation of chicken embryo cells by P3K or Akt can be interfered with by inhibiting the Akt-dependent phosphorylation of the inhibitor of NFkB (IkB) kinase (IKK) with the IkB-SR super repressor, resulting in downregulation of NFkB (Aoki and Vogt, 2003, unpublished observations) . These data suggest that a gain of NFkB function is required for P3K-or Akt-induced transformation in addition to a TOR-dependent stimulation of translation.
Our knowledge of PI3K signaling via TOR to the control of protein synthesis has recently been augmented by several new participants and interactions. The tuberous sclerosis complex consisting of the TSC1 and TSC2 proteins is a negative regulator of the signal and is positioned downstream of Akt and upstream of TOR (Gao and Pan, 2001; Inoki et al., 2002; Inoki et al., 2003) . Germline loss of function mutations suggest that the TSC proteins act as tumor suppressors (Montagne et al., 2001; Potter et al., 2001; Tapon et al., 2001) . Biochemically, they function as GTPase-activating proteins (GAP) and hence negative regulators for the Ras-like protein Rheb (Ras homolog enriched in brain) (Garami et al., 2003; Saucedo et al., 2003; Tee et al., 2003; Zhang et al., 2003b) . Akt-mediated phosphorylation inhibits the GAP activity of the TSC proteins, resulting in enhanced activity of Rheb, a positive regulator of TOR (Inoki et al., 2002; Inoki et al., 2003) .
Our understanding of TOR signaling proper has been refined by the discovery of the TOR signaling (TOS) motif in two important targets of TOR: S6K and 4E-BP (Schalm and Blenis, 2002 ). An intact TOS motif in S6K and 4E-BP is required for TOR-dependent phosphorylation. In 4E-BP a second motif, the RAIP motif, has been identified that is also important for TOR-mediated phosphorylation (Tee and Proud, 2002; Choi et al., 2003) . The TOS motifs are not bound by TOR directly. A newly isolated TOR-binding protein, Raptor (regulatory associated protein of TOR), mediates the interaction with TOS (Hara et al., 2002; Kim et al., 2002; Nojima et al., 2003; Schalm et al., 2003) . Currently available data are compatible with the suggestion that TOR binds Raptor and that this complex then binds to TOS domains of TOR substrates allowing phosphorylation of the substrates.
There are numerous genetic and epigenetic changes leading to increased PI3K signaling in human tumors. PIK3CA, the catalytic subunit of PI 3-kinase, is overexpressed in ovarian and cervical cancers and is frequently mutated in coloneatal and gastric cancers (Shayesteh et al., 1999; Ma et al., 2000; Samuels et al., 2004) . Akt is amplified or overexpressed in several cancers including gastric, breast, ovarian, pancreatic and prostate cancer (Cheng et al., 1992; Bellacosa et al., 1995; Cheng et al., 1996; Miwa et al., 1996; Ruggeri et al., 1998; Nakatani et al., 1999; Bacus et al., 2002; Liao et al., 2003) . PTEN shows loss of function in many tumors including carcinoma of the prostate, breast and glioblastoma (Li et al., 1997; Ali et al., 1999; Cantley and Neel, 1999; Maehama and Dixon, 1999; Depowski et al., 2001) . Constitutive phosphorylation of TOR is seen in prostate cancer cell lines that carry inactivating mutations of PTEN or overexpressed Akt (Sekulic et al., 2000) . 4E is overexpressed in lymphomas, cancers of the head and neck, in colon carcinomas and in cells containing elevated levels of the oncoprotein Myc (De Benedetti and Harris, 1999) . Rapamycin shows activity against numerous human cancer cell lines, inhibiting their growth in culture and as xenografts (Dilling et al., 1994; Dudkin et al., 2001; Geoerger et al., 2001; Neshat et al., 2001; Podsypanina et al., 2001; Houghton and Huang, 2004) .
Cancers that are dependent on a gain of function in the PI3K pathway are top candidates for therapeutic regimes that interfere with TOR signaling to the initiation of protein synthesis. The rapamycin derivative CCI 779 is currently undergoing clinical trials (Elit, 2002) . Additional targets for small molecule drugs in this pathway would be Rheb, 4E, 4E-BP and possibly S6K. The regulation of protein synthesis has become an important and promising area for the development of novel anticancer drugs.
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